Urothelial Carcinoma in the Community Overview

At the live virtual workshops, a three-member multidisciplinary expert faculty panel will provide both didactic presentations and collaborative open discussion with members of the multidisciplinary care team. Topics covered include, but are not limited to, a review of current evidence for the use of checkpoint inhibitors and novel agents, including antibody drug conjugates and fibroblast growth factor receptor (FGFR) inhibitors, patient selection criteria, and monitoring and managing immune-related adverse events (irAEs) in patients with advanced urothelial carcinoma. Collateral issues discussed include coordination and communication within the multidisciplinary care team, coverage and reimbursement, and fostering patient education and engagement.

During the workshop, participants will use the Institute for Healthcare Improvement's Plan-Do-Study-Act tool to develop a customized action plan. Workshop sites will report on their progress post-participation.

Continuing Education Credit available:

• Learning Workshops (CME/CNE/MOC credit provided – no CPE) – 4 credit hours
• Audio-guided Web Course (CME/CNE provided – no CPE, no MOC) – 1 credit hour

For more information on this project, please contact the ACCC Provider Education department.

Optimizing Outcomes for Patients With Urothelial Carcinoma: Recent Clinical Updates

With the evolving treatment landscape for urothelial carcinoma, community clinicians are challenged to keep abreast with evidence-based practice guidelines, the clinical efficacy for new therapies, monitoring and managing adverse events, and engaging patients sufficiently to help them make informed treatment decisions.

This one-hour, on-demand educational activity will allow participants to:

• Review available evidence for the use of checkpoint inhibitors and novel agents, including antibody drug conjugates and fibroblast growth factor receptor (FGFR) inhibitors.
• Explore strategies for identification and management of immune-related and FGFR inhibitor-associated adverse events.
• Outline effective solutions for improving coordination and communication within the multidisciplinary cancer care team to improve patient outcomes.

CME/CNE credits will be awarded for physicians and nurses.
Learn More & Register